TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

Inclusion Criteria

• •Histologically confirmed stage IV colon cancer (American Joint Committee on Cancer \[AJCC\] 7th edition) that has progressed after standard therapy that included fluorouracil (5-FU), irinotecan, oxaliplatin, bevacizumab (unless contraindicated) and an anti-EGFR antibody, if RAS wild type. Patients who could not tolerate standard agents because of unacceptable, but reversible toxicity necessitating their discontinuation will be allowed to participate
• •Patients who had received adjuvant chemotherapy and had recurrence during or within 6 months of completion of the adjuvant chemotherapy will be allowed to count the adjuvant therapy as one chemotherapy regimen
• •Progression of disease must be documented on the most recent scan
• •Presence of measurable disease
• •RAS mutation and mismatch repair deficiency (MMR) status must be determined (or tissue availability for testing if not already determined)
• •Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• •Life expectancy of at least 3 months
• •Absolute neutrophil count (ANC) \>= 1.5 x 10\^9/L
• •Hemoglobin \>= 9 g/dL
• •Platelets (PLT) \>= 75 x 10\^9/L
• •Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 5 x upper limit of normal (ULN)
• •Adequate contraception if applicable
• •Women who are nursing and discontinue nursing prior to enrollment in the program
• •Ability to take oral medication (i.e., no feeding tube)
• •Patient able and willing to comply with study procedures as per protocol
• •Patient able to understand and willing to sign and date the written voluntary informed consent form (ICF) at screening visit prior to any protocol-specific procedures